Loading data for HBIO — first visit, this takes a few seconds.
Harvard Bioscience, Inc. (HBIO)
NasdaqCM: HBIO
· Real-Time Price · USD
7.93
+0.03 (0.38%)
At close: Aug 28, 2026, 8:00 PM
7.93
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Harvard Bioscience, Inc. (HBIO) Stock Price, Analysis & Data
No data available
| Bid | 7.92 |
| Market Cap | 36.1M |
| Revenue (ttm) | 87.8M |
| Net Income (ttm) | -10.4M |
| 1.49 | |
| -2.33 | |
| n/a | |
| 12.29 | |
| P/B (ttm) | 4.87 |
| P/S (ttm) | 0.41 |
| Earnings Date | Aug 8, 2024 |
| Ask | 10.24 |
| Volume | 20,638 |
| Avg. Volume (20D) | 18,563 |
| Open | 8.00 |
| Previous Close | 7.90 |
| Day's Range | 7.91 - 8.00 |
| 52-Week Range | 3.80 - 9.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level...
Industry Medical Instruments & Supplies
Sector Healthcare
IPO Date Mar 19, 2001
Employees 316
Stock Exchange NasdaqCM
Ticker Symbol HBIO
Financial Performance
In 2025, Harvard Bioscience's revenue was 86.55M, a decrease of -8.06% compared to the previous year's 94.14M. Earnings were -56.7M, an increase of 357.07%.
Financial StatementsEarnings Surprise
Harvard Bioscience has released their quarterly earnings on Aug 11, 2026:
- Revenue of $20.76M misses estimates by $0, with -4.68% YoY decline.
- EPS of -0.14 exceeds estimates by 0.07, with -123.33% YoY decline.
Harvard Bioscience, Inc. is scheduled to release its earnings on Aug 8, 2024, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade

